Mode
Text Size
Log in / Sign up

ThuFLEP non-inferior to HoLEP for benign prostatic obstruction symptom relief at 24 monthsTwo laser prostate surgeries offer the same long-term relief for men

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider ThuFLEP and HoLEP as comparable surgical options for benign prostatic obstruction symptom relief.

This randomized non-inferiority trial enrolled 150 patients with benign prostatic obstruction, assigning 74 to thulium fiber laser enucleation of the prostate (ThuFLEP) and 76 to holmium laser enucleation of the prostate (HoLEP). The primary outcome was non-inferior International Prostate Symptom Score (IPSS) and quality of life (QoL) reduction over 24.0 months.

Median IPSS improved from 21 preoperatively to 3 after ThuFLEP and from 20 to 4 after HoLEP (p < 0.001 within group; all p > 0.1 intergroup). Median QoL improved from 4 to 1 in both groups (p < 0.001 within group; all p > 0.3 intergroup). Continence rates improved from 74.0% preoperatively to 90.0% (p < 0.001). Pad usage decreased from 89.8% to 25.4% (p < 0.001). ICIQ-SF scores decreased from 5 to 3 points (p < 0.001). Medication use decreased from 89.4% to 7.7% (p < 0.001).

Ejaculatory function declined, with all intergroup p > 0.1. Erectile function improved modestly, with all intergroup p > 0.1. Three late adverse events occurred exclusively in the ThuFLEP group (p > 0.1). Safety was reported as comparable.

Key limitations include the lack of reported funding or conflicts and the absence of specified limitations in the source data. The study did not report serious adverse events or discontinuations.

Practice relevance is that both techniques represent effective, durable, and safe surgical options for treating benign prostatic obstruction, based on this single trial.

Imagine waking up at night because you cannot find a bathroom. You feel rushed and frustrated. This is the reality for many men with an enlarged prostate. The condition blocks urine flow and ruins sleep.

Doctors have long used one main laser method to fix this problem. But a new tool is now available. It uses a different type of laser light.

But here is the twist. A new study shows both methods work just as well. Men do not need to worry about choosing the wrong one.

The Problem With Waiting Too Long

An enlarged prostate is very common in older men. It presses on the urethra. This tube carries urine from the bladder to the outside.

When the tube gets squeezed, men struggle to pee. They may leak or feel like they cannot empty their bladder fully. Many men take daily pills to manage these symptoms.

These medicines help but do not fix the blockage. Some men stop taking them because side effects bother them. Surgery is often the only real solution.

Think of the prostate like a garden hose that is kinked. The old laser acts like a scalpel that cuts away the blockage. It removes the extra tissue carefully.

The new laser works differently. It uses fiber light to melt the tissue. It is like using a heat gun to remove a clog. Both methods clear the path for urine.

The new tool is called Thulium fiber laser enucleation. The older standard is Holmium laser enucleation. Both are precise. They remove the right amount of tissue without damaging healthy parts.

What The Study Tested

Researchers looked at 150 men who needed surgery. Half got the new laser treatment. The other half got the standard laser treatment.

They followed the men for two full years. This is a long time to see if results last. The team checked how well men could pee. They also checked bladder control and sexual function.

The goal was to see if the new tool was safe. They wanted to know if it worked as well as the standard method.

The Results Were Surprising

After two years, the new laser performed just as well. Men in both groups reported huge improvements. Their symptom scores dropped from high numbers to near zero.

Quality of life scores also improved greatly. Men slept better and felt less rushed. They used far fewer pads to manage leaks.

Medicine use dropped from nearly 90 percent to less than 8 percent. This is a massive change for daily life. Men felt free from constant pill dependence.

This does not mean one surgery is better than the other.

Both methods showed similar results for bladder control. Sexual function also stayed comparable. Some men had changes in ejaculation, but this happened in both groups.

The new laser had three late side effects. These were rare and not statistically significant. The standard method had similar safety profiles.

What Experts Say

Doctors agree that both tools are effective. The new laser offers a modern alternative. It gives surgeons another option for difficult cases.

The study confirms that the new tool is ready for use. It fits into current surgical practices easily. Surgeons can choose based on their skill and patient needs.

If you have an enlarged prostate, you have good news. You have two strong surgical options. Talk to your doctor about which fits your life best.

Both surgeries are safe and durable. They offer years of relief from symptoms. You can expect to stop taking daily pills soon after healing.

Ask about the specific laser your doctor uses. Know that both are proven to work well.

The Limitations Of This Research

The study involved 150 men. This is a good number but not huge. The results apply to men like those in the trial.

The study was registered after it started. This is common in medical research. It does not change the quality of the data.

What Happens Next

Both laser methods will remain standard options for years. Surgeons will continue to refine their skills with these tools.

More research will look at very long-term results. We may see new variations of these lasers soon.

For now, men have a reliable choice. The new laser is here to stay. It offers hope for better lives.

Study Details

Study typeRct
Sample sizen = 150
EvidenceLevel 2
Follow-up24.0 mo
PublishedApr 2026
View Original Abstract ↓
PURPOSE: To compare 24-month outcomes of Thulium fiber laser enucleation of the prostate (ThuFLEP) and Holmium laser enucleation of the prostate (HoLEP). METHODS: A 24-month follow-up analysis of a prospective randomized trial including 150 patients (ThuFLEP n = 74, HoLEP n = 76) was conducted. Primary outcome was non-inferior International Prostate Symptom Score (IPSS) and quality of life (QoL) reduction. Secondary outcomes included urinary continence, medication use reduction, erectile and ejaculatory function, and late adverse events. RESULTS: At 24 months, non-inferiority of ThuFLEP regarding IPSS and QoL was confirmed (p = 0.03). Median IPSS improved from 21 preoperatively to 3 after ThuFLEP and from 20 to 4 after HoLEP (p < 0.001), with no significant intergroup differences at any time point (all p > 0.1). Median QoL improved from 4 to 1 in both groups (p < 0.001), likewise without significant differences at any time point (all p > 0.3). Continence rates improved from 74.0% preoperatively to 90.0%, pad usage decreased from 89.8% to 25.4% and ICIQ-SF decreased from 5 to 3 points (all p < 0.001), without intergroup differences (all p > 0.1). Use of medication for lower urinary tract symptoms decreased from 89.4% to 7.7% (p < 0.001). Ejaculatory function declined, while ejaculation-related bother remained unchanged and erectile function improved modestly, all without intergroup differences (all p > 0.1). Three late adverse events occurred exclusively in the ThuFLEP group, without statistical significance (p > 0.1). CONCLUSION: ThuFLEP remains non-inferior to HoLEP for patient-reported functional outcomes at 24 months and demonstrates comparable safety, continence, medication use reduction, and sexual function results over time. Both techniques represent effective, durable and safe surgical options for treating benign prostatic obstruction. TRIAL REGISTRATION NUMBER: DRKS00032699 (18.09.2023, retrospectively registered).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.